| |
 |
 |
| Company Name |
Novartis (Taiwan) Co., Ltd. |
| Protocol Number |
CICL670ATW01 |
| Title of Study |
Single-arm, Observational, Safety Evaluation of Exjade in Patients with Transfusion Hemosiderosis |
| Primary Objective |
The primary objective of this study is to evaluated the safety profile of Exjade in thalassemia treated for 2 years. |
| Number of Sites |
8 |
| Period of Study |
from 2008-11-08 to 2011-12-31 |
| Number of Patients |
130 |
| IRB Approval Date |
31-Oct-2008 |
| Publication Plan / Date |
30-Jun-2012 |
|
|
|
|
